A copper tripeptide studied specifically for follicle biology. KGF activation, follicle size, and how it differs from GHK-Cu for scalp and hair research.
AHK-Cu (Alanine-Histidine-Lysine Copper) is a synthetic tripeptide copper complex studied specifically for its activity in hair follicle biology. While its better-known cousin GHK-Cu is a broad-spectrum skin and wound-healing peptide, AHK-Cu has been investigated with a more targeted focus: what happens to keratinocyte growth factor (KGF) and hair follicle cycling when you apply a copper peptide directly to the scalp.
The research base for AHK-Cu is smaller than GHK-Cu — primarily preclinical animal studies and in vitro cell culture work — but the evidence that exists points consistently toward follicle-specific activation. It's categorized as a topical compound, not an injectable, which puts it in a different product class from most peptides in the research space.
AHK-Cu research consists primarily of preclinical animal models and in vitro studies. Limited human clinical trial data exists. Researchers should weigh this evidence grade when designing protocols.
The central mechanism studied in AHK-Cu research is its activation of keratinocyte growth factor (KGF) — also known as Fibroblast Growth Factor 7 (FGF-7). KGF is a protein produced by dermal papilla cells that signals keratinocytes (the cells that form hair shafts) to proliferate. It's one of the key molecular drivers of hair follicle cycling.
In preclinical studies, AHK-Cu has shown the ability to:
The copper ion plays a structural role — copper is a required cofactor for several enzymes involved in hair follicle maturation, including lysyl oxidase, which is critical for collagen and elastin cross-linking in the follicle's structural matrix.
Copper deficiency is associated with structural hair abnormalities in animal models. Copper peptides deliver the ion in a bioavailable, skin-penetrating form — and the tripeptide carrier also has its own biological activity independent of the copper.
The most-cited preclinical study on AHK-Cu demonstrated follicle size increases in an animal model, with investigators attributing the effect to KGF upregulation in dermal papilla cells. Vascular density in treated scalp tissue was also observed to increase, which is consistent with the copper complex's known angiogenic properties.
In vitro studies have confirmed the KGF upregulation mechanism in isolated dermal papilla cell cultures. The copper component appears necessary for the full effect — non-copper versions of the AHK tripeptide show reduced activity in cell-based assays.
Human clinical data is limited. Some cosmetic-industry studies have been conducted under proprietary formulations, but peer-reviewed human trial data with rigorous methodology is sparse compared to the animal and in vitro evidence base.
| Evidence Type | Finding | Strength |
|---|---|---|
| Animal models | Increased follicle size, KGF upregulation | Consistent, multiple studies |
| In vitro (cell culture) | KGF upregulation in dermal papilla cells | Good, mechanism confirmed |
| Human clinical trials | Limited peer-reviewed data | Sparse, mostly proprietary |
AHK-Cu is used topically, applied directly to the scalp. Concentration and carrier formulation both matter — the copper peptide needs a delivery vehicle that allows skin penetration without degrading the peptide.
| Parameter | Value |
|---|---|
| Concentration | 0.1–1% in carrier solution |
| Application site | Scalp (can also be used on skin) |
| Frequency | 1–2x daily |
| Carrier | Water-based serum or minoxidil solution |
| Cycle | Ongoing — effects are maintained with continued use |
AHK-Cu is often combined with minoxidil in research formulations — minoxidil provides direct vasodilation at the follicle while AHK-Cu targets the KGF pathway. The two mechanisms are complementary and their combination is commonly studied in hair biology research.
Both are copper tripeptides, both are used topically, and both appear in hair research. The distinction matters for protocol design.
| Feature | AHK-Cu | GHK-Cu |
|---|---|---|
| Sequence | Ala-His-Lys + Cu | Gly-His-Lys + Cu |
| Primary studied use | Hair follicle biology | Wound healing, skin repair, collagen |
| Key mechanism | KGF upregulation, follicle cycling | Fibroblast activation, collagen synthesis |
| Route | Topical | Topical or injectable |
| Evidence base | Moderate preclinical (hair-focused) | Extensive preclinical (broad-spectrum) |
| Hair-specific data | Strong — purpose-built for follicles | Some — incidental to broader skin research |
For hair-specific research, AHK-Cu is the more targeted compound. GHK-Cu has a larger overall evidence base but most of it addresses wound healing and skin repair rather than follicle cycling specifically. For general scalp health and collagen in the dermis, GHK-Cu is the broader option. For follicle-specific KGF activation, AHK-Cu is purpose-built.
Many researchers use both — AHK-Cu for the follicle-specific KGF mechanism, GHK-Cu for general scalp tissue quality and anti-inflammatory activity.
Vendor pricing and sourcing options for AHK-Cu.
View AHK-Cu Prices → GHK-Cu 101 Guide